TL1A Binding Antibodies With Selective CDR Targeting

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current biologics targeting TNF are associated with serious side effects, highlighting the need for improved therapies targeting TL1A to treat inflammatory diseases such as Crohn's disease and ulcerative colitis.

Innovation Solution

Development of a TL1A binding protein comprising specific CDR sequences in the heavy and light chain variable regions, optionally with immunoglobin Fc domain modifications, to selectively target TL1A and modulate its signaling.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If current biologics targeting TNF are used to treat inflammatory diseases, then therapeutic effect is achieved, but serious side effects occur

Engineering Contradiction:

Improvetherapeutic effectVSAvoidside effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent extracts the specific binding function from general TNF biologics by designing antibodies with precisely engineered CDR sequences that bind exclusively to TL1A, separating the desired therapeutic effect from the harmful side effects associated with broader TNF inhibition

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The patent applies local quality by optimizing specific regions (CDR sequences) of the antibody structure to achieve high-affinity binding to TL1A while maintaining selectivity, rather than modifying the entire antibody molecule, thereby achieving targeted therapy with reduced off-target effects

Inventive Principle:

Principle #3Local quality

2Object-affected harmful factors

If TL1A binding protein with specific CDR sequences is developed, then selectivity and reduced side effects are achieved, but manufacturing complexity increases

Engineering Contradiction:

Improveside effectsVSAvoidmanufacturing complexity

Core Design Contradiction:

Object-affected harmful factorsVSEase of manufacture

Solution Approach 1:

The patent specifies precise amino acid sequences for CDR regions (e.g., CDR1: SEQ ID NO: 5, CDR2: SEQ ID NO: 15, CDR3: SEQ ID NO: 25) to achieve optimal binding affinity and selectivity, using parameter optimization to balance therapeutic efficacy with manufacturability

Inventive Principle:

Principle #35Parameter changes

Data Source

PatentUS20260103531A1TL1a binding proteins and methods of use

Publication Date: 2026.04.16 PARAGON THERAPEUTICS INC

AI summary

Provided herein are TL1A binding proteins (e.g., antibodies that bind TL1A) and methods of use.